These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
626 related articles for article (PubMed ID: 26227906)
1. The Role of Cdk5 in Alzheimer's Disease. Liu SL; Wang C; Jiang T; Tan L; Xing A; Yu JT Mol Neurobiol; 2016 Sep; 53(7):4328-42. PubMed ID: 26227906 [TBL] [Abstract][Full Text] [Related]
2. Deregulated Cdk5 activity is involved in inducing Alzheimer's disease. Shukla V; Skuntz S; Pant HC Arch Med Res; 2012 Nov; 43(8):655-62. PubMed ID: 23142263 [TBL] [Abstract][Full Text] [Related]
3. Cyclin dependent kinase 5: A novel avenue for Alzheimer's disease. Bhounsule AS; Bhatt LK; Prabhavalkar KS; Oza M Brain Res Bull; 2017 Jun; 132():28-38. PubMed ID: 28526617 [TBL] [Abstract][Full Text] [Related]
4. Role of cdk5 in the pathogenesis of Alzheimer's disease. Lau LF; Ahlijanian MK Neurosignals; 2003; 12(4-5):209-14. PubMed ID: 14673207 [TBL] [Abstract][Full Text] [Related]
5. Sulforaphene, a CDK5 Inhibitor, attenuates cognitive deficits in a transgenic mouse model of Alzheimer's disease via reducing Aβ Deposition, tau hyperphosphorylation and synaptic dysfunction. Yang W; Xu QQ; Yuan Q; Xian YF; Lin ZX Int Immunopharmacol; 2023 Jan; 114():109504. PubMed ID: 36508924 [TBL] [Abstract][Full Text] [Related]
6. Silencing of CDK5 as potential therapy for Alzheimer's disease. López-Tobón A; Castro-Álvarez JF; Piedrahita D; Boudreau RL; Gallego-Gómez JC; Cardona-Gómez GP Rev Neurosci; 2011; 22(2):143-52. PubMed ID: 21476938 [TBL] [Abstract][Full Text] [Related]
7. Fuzhisan Ameliorates the Memory Deficits in Aged SAMP8 Mice via Decreasing Aβ Production and Tau Hyperphosphorylation of the Hippocampus. Zhang ZX; Zhao RP; Wang DS; Li YB Neurochem Res; 2016 Nov; 41(11):3074-3082. PubMed ID: 27518086 [TBL] [Abstract][Full Text] [Related]
8. Role of Cdk5 in Amyloid-beta Pathology of Alzheimer's Disease. Lu TT; Wan C; Yang W; Cai Z Curr Alzheimer Res; 2019; 16(13):1206-1215. PubMed ID: 31820699 [TBL] [Abstract][Full Text] [Related]
9. Cdk5, a therapeutic target for Alzheimer's disease? Tsai LH; Lee MS; Cruz J Biochim Biophys Acta; 2004 Mar; 1697(1-2):137-42. PubMed ID: 15023356 [TBL] [Abstract][Full Text] [Related]
10. Cdk5: one of the links between senile plaques and neurofibrillary tangles? Lee MS; Tsai LH J Alzheimers Dis; 2003 Apr; 5(2):127-37. PubMed ID: 12719630 [TBL] [Abstract][Full Text] [Related]
11. Deregulated Cdk5 triggers aberrant activation of cell cycle kinases and phosphatases inducing neuronal death. Chang KH; Vincent F; Shah K J Cell Sci; 2012 Nov; 125(Pt 21):5124-37. PubMed ID: 22899714 [TBL] [Abstract][Full Text] [Related]
13. Anti-diabetes drug pioglitazone ameliorates synaptic defects in AD transgenic mice by inhibiting cyclin-dependent kinase5 activity. Chen J; Li S; Sun W; Li J PLoS One; 2015; 10(4):e0123864. PubMed ID: 25875370 [TBL] [Abstract][Full Text] [Related]
14. Cdk5: multitasking between physiological and pathological conditions. Lopes JP; Agostinho P Prog Neurobiol; 2011 Jun; 94(1):49-63. PubMed ID: 21473899 [TBL] [Abstract][Full Text] [Related]
15. Neurodegeneration in an Abeta-induced model of Alzheimer's disease: the role of Cdk5. Lopes JP; Oliveira CR; Agostinho P Aging Cell; 2010 Feb; 9(1):64-77. PubMed ID: 19895631 [TBL] [Abstract][Full Text] [Related]